Trials / Completed
CompletedNCT02885662
Study of CS-3150 in Patients With Primary Aldosteronism
A Study of CS-3150 to Evaluate Efficacy and Safety in Patients With Primary Aldosteronism
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Daiichi Sankyo Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To examine antihypertensive effect and safety of CS-3150 in patients with primary aldosteronism.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CS-3150 | CS-3150 2.5 to 5.0 mg , orally. |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2017-07-20
- Completion
- 2017-07-20
- First posted
- 2016-08-31
- Last updated
- 2018-12-21
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02885662. Inclusion in this directory is not an endorsement.